Jake Bauer - 12 Feb 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: Director
Issuer ticker: ELVN
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 19:56:07 UTC
Prior SEC filing: 28 Aug 2025
Next SEC filing: 09 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Jake Bauer filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 17 Feb 2026.

Key facts

This page summarizes Jake Bauer's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 19:56.

Change

Previous filing in this sequence was filed on 28 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001654909 Primary reporting owner

Bauer Jake

Relationship: Director
Address: C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 17 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,126
Change %
Price: $0.000000
Shares after: 17,126
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,126
Exercise price: $27.16
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.